← Russell 3000 cross-section

PRAX Praxis Precision Medicines, Inc.

Trailing twelve months to 2025-12-31 · as filed 2026-02-19, not restated
Healthcare

Scale

Market cap
$10.4bn
Revenue TTM
$0m
Net income TTM
$-303m
Free cash flow
$-249m
Composite score
33.0
Sector rank
#697

Valuation

P / E
EV / EBITDA
EV / sales
FCF yield
-2.40%
Earnings yield vs 10-yr
-7.65pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
EBITDA margin
ROE
-34.5%
ROIC
-117.0%
Revenue growth
-100.0%

Insider activity, last 90 days

Net open-market
$-3.61m
Buyers
0
Sellers
1

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. General and Administrative Expense The $14.4 million increase in general and administrative expenses was primarily attributable to the following: • $7.2 million increase in professional expenses, primarily attributable to increased commercial spend as we prepare for the potential launches of ulixacaltamide and relutrigine; and • $6.3 million increase in personnel-related costs mainly due to increased headcount. …Praxis Precision Medicines, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →